Yazar "Sezgin, Aydan" seçeneğine göre listele

Listeleniyor 1 - 2 / 2
  • Küçük Resim
    Öğe
    Potential impact of obstetric history on postmenopausal fragility fracture risk: A reassessment of the Fracture Risk Assessment Tool
    (Turkish Joint Diseases Foundation, 2024) Sezgin, Aydan; Saçıntı, Huriye Güvenç; Osmanlı, Elşad; Mangır, Kübra; Saçıntı, Koray Görkem; Sezgin, Erdem Aras
    Objectives: This study aimed to evaluate the impact of integrating obstetric parameters into the Fracture Risk Assessment Tool (FRAX) on the precision of risk assessment. Patients and methods: In this retrospective study, patients who experienced postmenopausal fragility fractures of the distal radius, proximal femur, or lumbar vertebrae between January 1, 2021, and December 31, 2023, were included. Obstetric histories, along with standard FRAX parameters, were obtained by phone interviews. Based on the FRAX major osteoporotic fracture risk score calculated without bone mineral density, patients were classified into high-, intermediate-, and low-risk group categories. Differences in age at menarche, age at menopause, lactation duration, gravidity, and parity were analyzed across risk categories. Results: A total of 328 patients (mean age: 64.5±5.8 years; range, 55 to 75 years) were included. The mean FRAX score was 16±8.8 (range, 3 to 58), and 85, 191, and 52 patients were classified as high-, intermediate-, and low-risk, respectively. A positive correlation was observed between FRAX scores and both later age at menarche and earlier menopause (p<0.001 and p=0.008, respectively). The mean age at menopause was significantly different between the high- and low-risk groups (46.4 vs. 49.3 years, p=0.016). The intermediate-risk group was also evaluated, showing no significant differences in obstetric parameters compared to the low-risk group (p>0.05). Conclusion: Although late menarche is not explicitly included in FRAX, its association with higher fracture risk was evident. The established influence of early menopause on FRAX scores supports its role in fracture risk estimation. However, the inclusion of additional obstetric parameters did not enhance the predictive accuracy of FRAX in this cohort.
  • [ X ]
    Öğe
    The effects of hormone therapy on clinical symptoms
    (Nova Science Publishers, Inc., 2024) Sezgin, Aydan
    Menopause is difficult because of the clinical symptoms associated with hormonal changes. Every woman experiences these clinical symptoms to a greater or lesser extent. Hormone therapy has a particularly positive effect on vasomotor symptoms and genitourinary symptoms, but also on other symptoms. Hormone therapy consists mainly of estrogen preparations, and in women with a uterus, estrogen +progesterone preparations. There are various routes of administration of these preparations (oral, vaginal, and transdermal). However, since hormone therapy can increase the risk of cardiovascular disease, thromboembolic events, and breast cancer, the patient group to receive hormone therapy should be carefully selected.